Dr. Carol E. Cass This is Me

Education

 View all 196 references Web References

1. 1. Board of Directors

   keeper.cmc.ca/news/releases/do - [Cached]

   Published on: 7/24/2008   Last Visited: 7/24/2008

   New directors Dr. Carol Cass, Professor & Chair, Oncology, University of Alberta; Dr. Indira V. Samarasekera, Vice President Research, University of British Columbia; Mr. Brian Gerson, Vice-President, Mixed Signal Development, Analog Development, PMC-Sierra Inc.; and Dr. Richard Normandin (Board observer), Vice-President, Research, Physical Science, National Research Council Canada, will expand CMC's expertise in biomedical, physical science and metals and materials engineering.
   ...
   Dr. Carol Cass, Professor & Chair, Oncology; Canada Research Chair in Oncology; Adjunct Professor, Biochemistry, University of Alberta; and Associate Director (Research), Cross Cancer Institute

2. 2. Board of Directors

   www.cmc.ca/news/releases/docum - [Cached]

   Published on: 7/24/2008   Last Visited: 7/24/2008

   New directors Dr. Carol Cass, Professor & Chair, Oncology, University of Alberta; Dr. Indira V. Samarasekera, Vice President Research, University of British Columbia; Mr. Brian Gerson, Vice-President, Mixed Signal Development, Analog Development, PMC-Sierra Inc.; and Dr. Richard Normandin (Board observer), Vice-President, Research, Physical Science, National Research Council Canada, will expand CMC's expertise in biomedical, physical science and metals and materials engineering.
   ...
   Dr. Carol Cass, Professor & Chair, Oncology; Canada Research Chair in Oncology; Adjunct Professor, Biochemistry, University of Alberta; and Associate Director (Research), Cross Cancer Institute

3. 3. Dr. Carol Cass

   www.incc.cancer.ca/ncic/intern - [Cached]

   Published on: 5/27/2008   Last Visited: 6/16/2008

   Dr. Carol Cass
   
   2006 Dr. Carol Cass
   
   Dr. Carol Cass is recognized internationally for her work on understanding an important class of anti-cancer drugs called nucleosides.Dr. Cass has determined that nucleoside-based drugs are able to cross cell membranes by binding to specialized transporter proteins.When this binding occurs, the drugs are able to enter and directly attack cancer cells.Her research is leading to the more effective use of nucleoside drugs and the development of new treatments for patients with acute and chronic leukemias, lymphomas, and cancers of the lung, bladder, breast and pancreas.Dr. Cass has also played an important leadership role in training cancer researchers in translational research.
   
   Dr. Cass has been director of Alberta's Cross Cancer Institute in Alberta since 2003, making her the first basic scientist in Canada to serve as director of a comprehensive cancer centre.She is also chair of oncology and Canada research chair in oncology at the University of Alberta.